Aerpio initiates phase 1 trial of AKB-9778 for primary open-angle glaucoma

The first subject has been dosed in a phase 1b trial of the primary open-angle glaucoma treatment candidate AKB-9778, according to a press release from Aerpio Pharmaceuticals.

AKB-9778 binds to and inhibits vascular endothelial protein tyrosine phosphatase, a negative regulator of Tie2, the release said.

The multiple-ascending dose, double-masked trial will include four cohorts of 12 subjects who will receive increasing daily doses of topical AKB-9778 or placebo for 7 days. Ocular safety and tolerability are the primary endpoints of the trial.

“We have recently shown in animal models that topical ocular dosing of AKB-9778 lowers IOP via its action on Schlemm’s canal, and in two sequential phase 2 clinical studies, we have shown that subcutaneous administration of AKB-9778 significantly reduced IOP in ocular normotensive patients,” Kevin Peters, MD, Aerpio chief scientific officer, said in the release. “Based on these data, we believe that AKB-9778 could provide a novel and differentiated approach to treating POAG and the first approach that directly affects Schlemm’s canal.”

Study results are expected by the end of the year.

The first subject has been dosed in a phase 1b trial of the primary open-angle glaucoma treatment candidate AKB-9778, according to a press release from Aerpio Pharmaceuticals.

AKB-9778 binds to and inhibits vascular endothelial protein tyrosine phosphatase, a negative regulator of Tie2, the release said.

The multiple-ascending dose, double-masked trial will include four cohorts of 12 subjects who will receive increasing daily doses of topical AKB-9778 or placebo for 7 days. Ocular safety and tolerability are the primary endpoints of the trial.

“We have recently shown in animal models that topical ocular dosing of AKB-9778 lowers IOP via its action on Schlemm’s canal, and in two sequential phase 2 clinical studies, we have shown that subcutaneous administration of AKB-9778 significantly reduced IOP in ocular normotensive patients,” Kevin Peters, MD, Aerpio chief scientific officer, said in the release. “Based on these data, we believe that AKB-9778 could provide a novel and differentiated approach to treating POAG and the first approach that directly affects Schlemm’s canal.”

Study results are expected by the end of the year.